The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling
Open accessAbstract
The Glypican (GPC) family is a prototypical member of the cell‐surface heparan sulfate proteoglycans (HSPGs). The HSPGs have been demonstrated to interact with growth factors, act as coreceptors and modulate growth factor activity. Here we show that based on oligonucleotide array analysis, GPC3 was upregulated in hepatocellular carcinoma (HCC). By northern blot analysis, GPC3 mRNA was found to be upregulated in 29 of 52 cases of HCC (55.7%). By Western blot analysis carried out with a monoclonal anti‐GPC3 antibody we generated, the GPC3 protein was found to be overexpressed in 6 hepatoma cell lines, HepG2, Hep3B, HT17, HuH6, HuH7 and PLC/PRF/5, as well as 22 tumors (42.3%). To investigate the role of overexpressed GPC3 in liver cancer, we analyzed its effects on cell growth of hepatoblastoma‐derived cells. Overexpression of GPC3 modulated cell proliferation by inhibiting fibroblast growth factor 2 (FGF2) and bone morphogenetic protein 7 (BMP‐7) activity. An interaction of GPC3 and FGF2 was revealed by co‐immunoprecipitation, while GPC3 was found to inhibit BMP‐7 signaling through the Smad pathway by reporter gene assay. The modulation of growth factors by GPC3 may help explain its role in liver carcinogenesis. In addition, the ability of HCC cells to express GPC3 at high levels may serve as a new tumor marker for HCC. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., & Ornitz, D. M. (1991) · Cell · doi:10.1016/0092-8674(91)90512-w · Cited by 2,440
Cited by
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Zhou, F., Shang, W., Yu, X., & Tian, J. (2018) · Medicinal Research Reviews · doi:10.1002/med.21455 · Cited by 397
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K.-I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800436 · Cited by 338
Self-citationPrecision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 301
Metadata
- Authors
- Midorikawa, Y., Ishikawa, S., Iwanari, H., Imamura, T., Sakamoto, H., Miyazono, K., Kodama, T., Makuuchi, M., & Aburatani, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-11-21
- Volume
- 103
- Issue
- 4
- Pages
- 455-465
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1977415499
- Cited by
- 238
- References
- 1
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling. https://app.cochat.ai/papers/10.1002/ijc.10856
- The paper
- Midorikawa, Y., Ishikawa, S., Iwanari, H., Imamura, T., Sakamoto, H., Miyazono, K., Kodama, T., Makuuchi, M., & Aburatani, H. (2003). Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling. International Journal of Cancer. https://doi.org/10.1002/ijc.10856
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.